Merck protease inhibitor trial seeks persons with CD4 count under 50.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage; D018791:CD4 Lymphocyte Count / Q000187:drug effects*; D004345:Drug Industry; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015277:Hotlines; D006801:Humans; D019469:Indinavir; D019259:Lamivudine; D018579:Patient Selection; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D015215:Zidovudine / Q000008:administration & dosage
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D016047:Zalcitabine